Eli Lilly's Obesity Pill Shows Promise for Weight Loss Maintenance

Eli Lilly's Obesity Pill Trial Results

• 💡 Eli Lilly's new obesity pill has shown effectiveness as a maintenance treatment for preserving weight loss.
• 🎯 In a trial, patients who switched from weekly injections (Wegovy or Zepbound) to the pill maintained the majority of their lost weight over a year.
• 📈 Patients on the Wegovy group regained only about 2 pounds, while those on Zepbound regained around 11 pounds after a year on the pill.

Market Potential and Pricing

• 🚀 This data suggests the pill could play a significant role in the weight loss drug market as a maintenance option, potentially boosting drug uptake.
• 💰 While exact pricing is not yet announced, a deal with President Trump indicated a starting cash price of $150 per month for the pills via Trump RX.
• 💸 This $150 price point is considerably lower than the approximately $1,000 per month cost for the injectable versions before insurance.

Insurance Coverage Expansion

• ⚠️ Current obesity drug coverage by insurance is inconsistent.
• ✅ However, a recent deal is expected to expand Medicare coverage to include obesity drugs for the first time, likely in early to mid-2026.